ArticleCurrent medicinal chemistry2026
Nanomaterial Enhances the Performance of Amyloid-beta Biosensing for Alzheimer's Disease Diagnosis.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHighly sensitive, accurate, and low-cost detection systems are gaining interest for early intervention in the progression of Alzheimer's disease (AD). Amyloid-beta (Aβ), a peptide highly involved in the progression of AD, is found in abundance in patients with severe AD.
objectiveThis research focused on developing an Aβ oligomer (AβO) biosensor using a single-walled carbon nanotube-modified (SWCN) interdigitated electrode (IDE) sensor.
methodsThe SWCN was functionalized onto the sensor surface through an amine linker, followed by the attachment of an aptamer-gold nanoparticle (GNP) complex, which was used to capture the AβO.
resultsThe GNP-aptamer was saturated at 500 nM on the SWCN surface, and AβO was detected using a sandwich consisting of aptamer-AβO-antibody. The SWCN modification increased the number of aptamer attachment sites on the IDE, while the aptamer and antibody conjugation with GNP enhanced AβO interaction. This sandwich assay detected AβO at concentrations as low as 10 fM, with a linear regression coefficient (y = 2.9189x - 2.076; R
conclusionThis SWCN modified IDE-based sandwich detects AβO at its lower level and contributes to the early diagnosis of AD.
Indexed as
Identifiers
40337966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.